Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.

Ideaya Biosciences, a US-based precision medicine developer backed by corporates Alphabet, Celgene, Novartis, Roche and WuXi AppTec, raised $50m on Friday in an initial public offering on the Nasdaq Global Select Market. The company issued 5 million shares priced at $10.00 each, representing an offering downsized from a range of $13 to $15. Its shares…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.